Trump's Prescription for Profits: How Drug Pricing Deals Mask Deeper Issues The White House's announcement of new drug pricing deals with nine midsized pharmaceutical companies has been touted as a victory for President Trump's efforts to tackle high prescription costs.
However, this development raises more questions than answers about the true drivers of healthcare affordability in America.
Beneath the surface, this appears to be another chapter in the administration's playbook of using executive orders and public relations stunts to mask deeper structural issues plaguing the industry.